These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37661647)

  • 1. Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study.
    Ma H; Zhu H; Chen F; Yang Y; Qu X; Xu H; Yang L; Zhang R
    Epilepsia Open; 2023 Dec; 8(4):1474-1483. PubMed ID: 37661647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study.
    Gao L; Lu Q; Wang Z; Yue W; Wang G; Shao X; Guo Y; Yi Y; Hong Z; Jiang Y; Xiao B; Cui G; Gao F; Hu J; Liang J; Zhang M; Wang Y
    Front Neurol; 2023; 14():1236046. PubMed ID: 37712083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of perampanel monotherapy after adjunctive therapy through retention rate in subjects with focal-onset seizures with or without focal to bilateral tonic-clonic seizures: A multicenter retrospective study in Korea.
    Lim SC; Lee WG; Kim DW; Kim KK; Shon YM; Park J; Lee Y; Seo DW
    Epilepsy Behav; 2023 Aug; 145():109291. PubMed ID: 37336136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience.
    Chinvarun Y
    Epilepsia Open; 2022 Mar; 7(1):67-74. PubMed ID: 34741590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures:A real-world experience in eastern China.
    Xu S; Xu ZY; Zheng Y; Miao P; Feng J; Guo Y
    Seizure; 2023 Aug; 110():231-237. PubMed ID: 37437408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
    Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
    Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
    Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
    Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.
    Wang Q; Xu Y; Chen Y; Wu X; Ge Y; Zhu G
    Epilepsy Behav; 2022 Nov; 136():108937. PubMed ID: 36215830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM).
    Husni RE; Ngo LY; Senokuchi H; Patten A; Hiramatsu H; Watanabe K; Yamamoto T
    Epilepsia Open; 2022 Mar; 7(1):59-66. PubMed ID: 34657389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study).
    Yamamoto T; Lim SC; Ninomiya H; Kubota Y; Shin WC; Kim DW; Shin DJ; Hoshida T; Iida K; Ochiai T; Matsunaga R; Higashiyama H; Hiramatsu H; Kim JH
    Epilepsia Open; 2020 Jun; 5(2):274-284. PubMed ID: 32524053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry.
    Toledano Delgado R; García-Morales I; Parejo-Carbonell B; Jiménez-Huete A; Herrera-Ramirez D; González-Hernández A; Ayuga Loro F; Santamarina E; Toledo M; Ojeda J; Poza JJ; Molins A; Giner P; Estévez María JC; Castro-Vilanova MD; Zurita J; Saiz-Diaz RA; Gómez-Ibañez A; Rodriguez-Uranga J; Gil-Nagel A; Campos D; Sánchez-Larsen Á; Aguilar-Amat Prior MJ; Mauri Llerda JA; Huertas González N; García-Barragán N
    Epilepsia; 2020 Jun; 61(6):1109-1119. PubMed ID: 32511754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.